#ESMO26, TALAPRO-3 showed improved rPFS with talazoparib + enzalutamide in HRR-altered mCSPC without clinically meaningful deterioration in overall QoL versus enzalutamide alone

Deborah Mukherji· @dmukherji · X·2026-10-23 20:44· 2 days agoScore70

Body

Important benefit–risk data for treatment intensification @AzadOncology @OncoAlert

335 views · 8 likes · 8 reposts · 0 replies

Conference abstracts

2219RONCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta

https://esmocongress.esmo.org

Source: Deborah Mukherji · x.com